Viral hepatitis: Response-guided strategy to reduce DAA duration for hepatitis C

  • Katrina Ray
  • Published 2016 in Nature Reviews Gastroenterology &Hepatology

Abstract

In a proof-of-concept study, Lau et al. have shown that the treatment course of direct-acting antiviral agents (DAAs) can be reduced to 3 weeks and still be effective using a response-guided approach. Patients with chronic hepatitis C (genotype 1b) without cirrhosis were randomly allocated to receive one of three different triple DAA regimens: sofosbuvir, ledipasvir and asunaprevir (n = 12); sofosbuvir, daclatasvir and simeprevir (n = 6); or sofosbuvir, daclatasvir and asunaprevir (n = 8). Only those who demonstrated an ultra-rapid virologic response to DAAs by day 2 had their treatment course reduced from the standard 12 weeks to 3 weeks, achieving virologic ‘cure’ by week 3 with excellent tolerability. The authors hope that shortening the duration of therapy could substantially reduce treatment costs, but large-scale studies of this approach are needed.

DOI: 10.1038/nrgastro.2016.150

Cite this paper

@article{Ray2016ViralHR, title={Viral hepatitis: Response-guided strategy to reduce DAA duration for hepatitis C}, author={Katrina Ray}, journal={Nature Reviews Gastroenterology &Hepatology}, year={2016}, volume={13}, pages={558-558} }